New Delivery Technologies Make Peptide Drugs Possible Without Injections: Aquasomes and Microneedles
Aquasomes (ceramic nanoparticles) and microneedles offer promising alternatives to injections for delivering peptide drugs via oral and transdermal routes while maintaining stability and bioavailability.
Quick Facts
What This Study Found
Aquasomes enhance peptide stability through ceramic core-polyhydroxy oligomer coating for oral delivery. Microneedles (150-1500 μm) create transdermal pathways for peptide drugs. Both approaches address the key barriers of oral degradation and skin impermeability.
Key Numbers
Aquasomes preserve peptide activity; microneedles enable painless transdermal delivery at micrometer scale.
How They Did This
Review of recent advances in peptide drug delivery focusing on oral and transdermal routes, with detailed discussion of aquasome nanoparticle design and microneedle technology types and mechanisms.
Why This Research Matters
Patient compliance with injectable peptide drugs is a major clinical challenge. Alternative delivery routes could make peptide therapeutics more accessible and improve treatment adherence, especially for conditions requiring daily dosing.
The Bigger Picture
As the peptide drug pipeline grows (GLP-1 agonists, antimicrobial peptides, etc.), delivery technology becomes the critical bottleneck. Technologies like aquasomes and microneedles could dramatically expand patient access to peptide therapeutics.
What This Study Doesn't Tell Us
Review of technologies at various development stages — many not yet clinically validated. Scale-up manufacturing challenges for both aquasomes and microneedles. Regulatory pathways for novel delivery devices are complex.
Questions This Raises
- ?Can aquasomes achieve sufficient oral bioavailability for potent peptide drugs like insulin?
- ?Are microneedle patches practical for self-administration of peptide drugs at home?
- ?Which peptide drugs are best suited for each delivery platform?
Trust & Context
- Key Stat:
- 150-1500 μm microneedle length range for painless transdermal peptide drug delivery
- Evidence Grade:
- Review of emerging delivery technologies at various development stages. Conceptual frameworks are well-supported but clinical validation data is limited.
- Study Age:
- Published in 2021. Both aquasome and microneedle technologies continue to advance toward clinical application.
- Original Title:
- Advanced trends in protein and peptide drug delivery: a special emphasis on aquasomes and microneedles techniques.
- Published In:
- Drug delivery and translational research, 11(1), 1-23 (2021)
- Authors:
- Asfour, Marwa Hasanein
- Database ID:
- RPEP-05266
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why can't most peptide drugs be taken as pills?
Stomach acid and digestive enzymes rapidly break down peptide drugs before they can be absorbed. Technologies like aquasome nanoparticles protect peptides from degradation during their journey through the digestive system.
Are microneedle patches painful?
No — microneedles are so small (thinner than a hair) that they typically cause no pain or bleeding. They create tiny channels just through the outer skin layer, allowing peptide drugs to pass through without the discomfort of traditional injections.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05266APA
Asfour, Marwa Hasanein. (2021). Advanced trends in protein and peptide drug delivery: a special emphasis on aquasomes and microneedles techniques.. Drug delivery and translational research, 11(1), 1-23. https://doi.org/10.1007/s13346-020-00746-z
MLA
Asfour, Marwa Hasanein. "Advanced trends in protein and peptide drug delivery: a special emphasis on aquasomes and microneedles techniques.." Drug delivery and translational research, 2021. https://doi.org/10.1007/s13346-020-00746-z
RethinkPeptides
RethinkPeptides Research Database. "Advanced trends in protein and peptide drug delivery: a spec..." RPEP-05266. Retrieved from https://rethinkpeptides.com/research/asfour-2021-advanced-trends-in-protein
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.